FATE Fate Therapeutics Inc
Price (delayed)
$1.35
Market cap
$154.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.64
Enterprise value
$193.69M
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture
Highlights
The debt has declined by 18% year-on-year and by 14% since the previous quarter
The gross profit has dropped by 79% year-on-year
FATE's revenue has dropped by 79% year-on-year
Key stats
What are the main financial stats of FATE
Market
Valuations
Earnings
Shares outstanding
114.6M
Market cap
$154.71M
Enterprise value
$193.69M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.48
Price to sales (P/S)
11.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.21
Revenue
$13.63M
Gross profit
$13.63M
Operating income
-$210.28M
Net income
-$186.26M
EBIT
-$186.26M
EBITDA
-$167.3M
Free cash flow
-$123.6M
Per share
Balance sheet
Liquidity
EPS
-$1.64
EPS diluted
-$1.64
Free cash flow per share
-$1.09
Book value per share
$2.8
Revenue per share
$0.12
TBVPS
$3.88
Total assets
$440.69M
Total liabilities
$121.97M
Debt
$85.27M
Equity
$318.73M
Working capital
$253.39M
Debt to equity
0.27
Current ratio
7.58
Quick ratio
7.6
Net debt/EBITDA
-0.23
Margins
Efficiency
Dividend
EBITDA margin
-1,227.3%
Gross margin
100%
Net margin
-1,366.5%
Operating margin
-1,542.6%
Return on assets
-36.6%
Return on equity
-49.5%
Return on invested capital
-37.6%
Return on capital employed
-46.3%
Return on sales
-1,366.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FATE stock price
How has the Fate Therapeutics stock price performed over time
Intraday
1.5%
1 week
21.62%
1 month
43.49%
1 year
-68.6%
YTD
-18.18%
QTD
70.86%
Financial performance
How have Fate Therapeutics's revenue and profit performed over time
Revenue
$13.63M
Gross profit
$13.63M
Operating income
-$210.28M
Net income
-$186.26M
Gross margin
100%
Net margin
-1,366.5%
The gross profit has dropped by 79% year-on-year
FATE's revenue has dropped by 79% year-on-year
The net income has contracted by 16% YoY and by 4.5% from the previous quarter
FATE's operating income is down by 10% year-on-year and by 7% since the previous quarter
Growth
What is Fate Therapeutics's growth rate over time
Valuation
What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
0.48
P/S
11.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.21
FATE's price to book (P/B) is 90% lower than its 5-year quarterly average of 5.0 and 56% lower than its last 4 quarters average of 1.1
The company's equity fell by 13% YoY and by 12% QoQ
The stock's price to sales (P/S) is 86% less than its 5-year quarterly average of 81.1 and 77% less than its last 4 quarters average of 47.6
FATE's revenue has dropped by 79% year-on-year
Efficiency
How efficient is Fate Therapeutics business performance
The ROIC has contracted by 34% YoY and by 8% from the previous quarter
The ROE has contracted by 30% YoY and by 8% from the previous quarter
Fate Therapeutics's return on assets has decreased by 29% YoY and by 8% QoQ
FATE's return on sales is down by 3.1% since the previous quarter
Dividends
What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FATE.
Financial health
How did Fate Therapeutics financials performed over time
FATE's total assets is down by 13% year-on-year and by 11% since the previous quarter
FATE's current ratio is down by 11% YoY and by 9% from the previous quarter
The debt is 73% smaller than the equity
The debt has declined by 18% year-on-year and by 14% since the previous quarter
The company's equity fell by 13% YoY and by 12% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.